An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.
Patients must meet all of the following criteria at Baseline:
Patients initiating Hyrimoz® treatment.
Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC.
Patients ≥ 18 years of age.
Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study.
Patients meeting one of the following criteria:
Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria).
Referred to as "biologic-naive patients": Patients who had an inadequate response or contraindications to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a first-line biologic therapy according to the summary of product characteristics (SmPC).
Patients able to complete and understand the self-administered questionnaires.
Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
Patients enrolled in an ongoing interventional study.
Patients with any contraindications to Hyrimoz® according to the SmPC.
Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula).
Use of any investigational drug in last 6 months prior to enrollment.
Sandoz Investigational Site
If the location of your choosing does not feature any contact detail, please reach out using the information below.